Browse the corpus

Edoxaban belongs to the class of direct oral anticoagulants (DOACs) and is used for the treatment of pulmonary embolism (PE), deep venous thrombosis (DVT), and to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). This drug exerts its therapeutic effects by inhibiting factor Xa directly, selectively, and reversibly as part of its mechanism of action. In contrast to the widely used anticoagulant warfarin, edoxaban offers the advantage of fewer monitoring requirements, lower risk of substantial bleeding, and infrequent drug interactions. This activity outlines the indications, mechanism of action, and contraindications for edoxaban as a valuable agent in treating and managing thromboembolic events. This activity also highlights the adverse event profile and other crucial considerations related to edoxaban that are essential for healthcare professionals involved in caring for patients with PE, DVT, and NVAF. Objectives: Identify the appropriate patient populations, including those with pulmonary embolism, deep venous thrombosis, and non-valvular atrial fibrillation, who could benefit from edoxaban therapy. Screen patients for renal function and creatinine clearance before edoxaban therapy to determine appropriate dosages and assess contraindications. Implement appropriate dosing regimens and treatment plans for patients receiving edoxaban to ensure its safe and effective use. Communicate with patients effectively about the risks, benefits, and potential adverse effects of edoxaban therapy to facilitate informed decision-making. Access free multiple choice questions on this topic.

Patients with impaired kidney function have a higher risk of toxicity. The efficacy of hemodialysis in enhancing edoxaban clearance has not been established. Management of Overdose In cases of overdose or toxicity during bleeding or hemorrhage, general measures can be contemplated, including discontinuing the medication, using mechanical compression, sustaining volume, and replacing hematologic components.[14] Activated charcoal could also be an alternative option if the medication were ingested within the preceding 2 hours.[14] The effects of the agents could potentially endure for up to 24 hours.[15] Although no approved or licensed reversal therapy exists for edoxaban, prothrombin complex concentrates (PCCs) are commonly used in pathological bleeding cases.[16] The use of PCCs in bleeding individuals has a minimal logical explanation. Although PCCs replenish clotting factors FII, FVII, and FIX, edoxaban operates downstream of the actions of PCCs within the coagulation cascade.[14][16]. Protamine sulfate, vitamin K, and tranexamic acid are not anticipated to counteract the anticoagulant effects of edoxaban.[16]

Edoxaban is an FDA-approved DOAC indicated for managing VTE and PE and preventing stroke and SE risk in patients with NVAF. The healthcare provider, whether a primary care clinician or specialist, responsible for prescribing the medication should be familiar with the most recent anticoagulation guidelines, clinical trial findings concerning edoxaban, and its indications and potential adverse effects. Caring for patients with thromboembolic diseases requires a vigilant interprofessional healthcare team to prevent permanent complications and mortality from preventable ischemic events. This interprofessional healthcare team includes a primary care clinician, a hematologist, a cardiologist, a pulmonologist, nurses, and pharmacists. The use of an interprofessional approach is poised to enhance patient outcomes and proactively avert adverse events by coordinating and aligning their efforts and exchanging information as a unified team. Primary care clinicians and specialists should take the initiative to educate their patients about the potential outcomes of noncompliance with anticoagulant therapy over the entire prescribed duration. Emphasizing the risks of subtherapeutic levels can help patients understand the connection between inadequate dosing and heightened probabilities of thromboembolism and ischemic complications. Before initiating the treatment, the prescriber should establish the patient's baseline liver and kidney function and CrCl levels. This initial assessment is crucial, as dosage adjustments are necessary for individuals with a CrCl of 15 to 50 mL/min. The medication is contraindicated for those with a CrCl <15 mL/min. Patients should be provided comprehensive information about the potential common adverse effects of edoxaban therapy, including bleeding risk, rash, and anemia. Regular checkups should be scheduled, and routine monitoring of liver function is essential, as edoxaban treatment might lead to an elevation in liver enzymes. The prescriber of the medication should be aware of the incompatibility of edoxaban with certain P-gp inhibitors. In this scenario, the involvement of a pharmacist in medication reconciliation can prove invaluable.

Patients should be provided comprehensive information about the potential common adverse effects of edoxaban therapy, including bleeding risk, rash, and anemia. Regular checkups should be scheduled, and routine monitoring of liver function is essential, as edoxaban treatment might lead to an elevation in liver enzymes. The prescriber of the medication should be aware of the incompatibility of edoxaban with certain P-gp inhibitors. In this scenario, the involvement of a pharmacist in medication reconciliation can prove invaluable. Pregnancy requires thorough counseling and vigilant monitoring due to the limited clinical studies on edoxaban's use during pregnancy. Moreover, healthcare providers administering spinal or epidural puncture procedures should exercise caution when dealing with patients on anticoagulants, given the substantial risk of spinal and epidural hematoma, which can lead to permanent impairment. Patients must be thoroughly educated about not using edoxaban concurrently with other hematological agents, as such combinations might heighten the patient's susceptibility to pathological bleeding. Effective interprofessional communication and a shared decision-making approach between healthcare providers and patients are pivotal in cultivating trust and fostering a therapeutic alliance with patients. This approach aids in ensuring patients adhere to therapy, thus minimizing the likelihood of thromboembolism-related complications and achieving the best possible outcomes.